RSS   Newsletter   Contact   Advertise with us
Post Online Media

NantKwest appoints Fred Driscoll to board

NantKwestSeptember 25, 2017, Culver City, Ca., USA - NantKwest, a clinical-stage immunotherapy company, announced that Fred Driscoll has been appointed to the board.
Joining NantKwest’s Board, Mr. Driscoll brings more than 30 years of deep financial and commercialization experience in the biotechnology and medical device industries.

Prior to joining NantKwest, Mr. Driscoll has been an Advisor of Flexion Therapeutics, Inc. and served as the Chief Financial Officer of Flexion Therapeutics, Inc. from 2013 until his retirement earlier this year.

Prior to Flexion, he served as the Chief Financial Officer, Vice President, Treasurer and Principal Accounting Officer of Novavax, Inc.

He served as the Chief Executive Officer and President at Genelabs Technologies, Inc. and also served as its Chief Financial Officer.

Earlier in his career, Mr. Driscoll was Chief Financial Officer of Astraris, Inc., Chief Executive Officer and President of OXiGENE, Inc., and Senior Vice President of Finance and Operations of Collagenesis Corporation.

He has more than 30 years of financial management experience with biotechnology and medical device companies.

Mr. Driscoll has a Bachelor’s degree in Accounting and Finance from Bentley University in Waltham, Massachusetts.




POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.